Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15280MR)

This product GTTS-WQ15280MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioma Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15280MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10343MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ3867MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ8302MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ14887MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ13213MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ1697MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ12198MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ6689MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW